This case was reported by a consumer, via a GSK nurse educator, and described
the occurrence of signs of pml in a 46-year-old female patient who received
Belimumab (Benlysta) for systemic lupus erythematosus. A physician or other
health care professional has not verified this report.
Concurrent medical conditions included systemic lupus erythematosus. 
On August 2012 the patient started Belimumab (unknown), unknown dosing. At an
unknown time after starting Belimumab, the patient experienced signs of pml,
dizziness, trouble thinking, reversing numbers and bone pain. This case was
assessed as medically serious by GSK. At the time of reporting, the events
were unresolved.
In January 2013, the patient experienced bone pain. At an unknown date, after
starting Belimumab, the patient experienced PML type side effects that were
described as dizziness, trouble thinking and difficulty with numbers. The
patient experiences these side effects about week 3 or 4 before next
infusion.
Print Time: 24-MAY-2016 07:56 AM If a field is blank, there is no data for that field Page 321 of 570
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information